Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
- Conditions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Dutch Childhood Oncology Group
- Target Recruit Count
- 445
- Registration Number
- NCT00550992
- Locations
- 🇨🇿
University Hospital Motol, Prague, Czechia
🇫🇷CHR Hotel Dieu, Nantes, France
🇺🇸Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
- Conditions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT00550784
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
- Conditions
- Interventions
- Biological: filgrastimDrug: CyclophosphamideDrug: BusulfanDrug: CyclosporineDrug: Fludarabine phosphateDrug: Mycophenolate MofetilDrug: MelphalanProcedure: allogeneic hematopoietic stem cell transplantationProcedure: umbilical cord blood transplantationRadiation: Fractionated total body irradiationRadiation: total-body irradiation
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT00547196
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸Banner Good Samaritan Medical Center, Phoenix, Arizona, United States
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
- Conditions
- Interventions
- Drug: cyclosporineDrug: cyclophosphamideDrug: busulfanDrug: etoposideDrug: fludarabine phosphateDrug: melphalanDrug: methotrexateDrug: mycophenolate mofetilDrug: sirolimusDrug: tacrolimusProcedure: allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationRadiation: total-body irradiation
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 260
- Registration Number
- NCT00544115
Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 75
- Registration Number
- NCT00544466
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
High-Dose Chemotherapy in Treating Patients Undergoing Stem Cell Transplant for Recurrent or Refractory Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2010-02-09
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT00544570
Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2007-10-04
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00539500
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
- Conditions
- Adult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Nasal Type Extranodal NK/T-cell LymphomaChildhood Acute Lymphoblastic Leukemia in Remission
- Interventions
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 174
- Registration Number
- NCT00536601
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT00536978
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma
- Conditions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2015-07-16
- Target Recruit Count
- 360
- Registration Number
- NCT00526318
- Locations
- 🇩🇪
Klinikum Augsburg, Augsburg, Germany
🇩🇪Evangelisches Krankenhauus Bielfeld, Biefeld, Germany
🇩🇪Klinikum Duisburg, Duisburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.